CD24 and neoplasm: Recent studies have elucidated the presence of a CD133+/CD24+ cell subpopulation in ccRCC, which promotes angiogenesis within the TME and contributes to resistance against multitarget tyrosine kinase inhibitors, leading to tumor progression and poor prognosis.